TLGY Acquisition Corporation Announces Closing of Upsized $200 million Initial Public Offering

Rhea-AI Summary

TLGY Acquisition Corporation has successfully closed its initial public offering, raising $200 million through the sale of 20 million units priced at $10.00 each. The units are listed on the NASDAQ under the ticker symbol TLGYU. Each unit includes one Class A ordinary share and warrants. TLGY plans to pursue business combinations primarily in the global biopharma and technology-enabled B2C sectors. Mizuho Securities and Baird managed the offering, with an option for underwriters to purchase an additional 3 million units.

Positive

• Raised $200 million in gross proceeds through IPO.
• Focus on lucrative biopharma and technology-enabled B2C sectors.
• Experienced leadership team with strong backgrounds.

Negative

• None.

NEW YORK--(BUSINESS WIRE)-- TLGY Acquisition Corporation (the “Company” or “TLGY”) announced today that it closed its initial public offering of 20,000,000 units priced at $10.00 per unit, resulting in gross proceeds of $200,000,000. The units are listed on the NASDAQ Global Market and trade under the ticker symbol “TLGYU". Each unit consists of one Class A ordinary share and one-half of one redeemable warrant and a contingent right to receive at least one-fourth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Company expects that the Class A ordinary shares and warrants will be listed on the NASDAQ Global Market under the symbols "TLGY" and “TLGYW”, respectively.

TLGY is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. While the Company may pursue an acquisition or business combination target in any business or industry, it intends to focus its search on the global biopharma or technology enabled business-to-consumer (“B2C”) industries.

TLGY is led by Jin-Goon Kim, a former partner of TPG Capital and a former CEO of industry leaders in Asia, including Dell Korea and Li Ning. Jin-Goon Kim is joined by Co-Presidents, Dr. Theron Odlaug, who has more than 40 years of experience as a CEO, Board Member and Senior Executive of pharmaceutical and allied companies, and Steven Norman, who has more than 20 years of experience as an executive and a director in the Asia-Pacific technology space.

Mizuho Securities acted as the sole bookrunner for the offering, and Baird acted as lead manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 units to cover over-allotments, if any.

Registration statements relating to these securities have been filed with, and declared effective by, the Securities and Exchange Commission (“SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The public offering was made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained for free by visiting EDGAR on the website of the U.S. Securities and Exchange Commission (the "SEC") at https://www.sec.gov/edgar/browse/?CIK=1879814&owner=exclude. Alternatively, copies of the prospectus may be obtained from Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, New York 10020; Telephone: 212-205-7600.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005386/en/

Jin-Goon Kim

Founder and Chief Executive Officer

+852 9731 0995

mail@tlgyacquisition.com

Website: www.tlgyacquisition.com

Source: TLGY Acquisition Corporation

FAQ

What was the total amount raised by TLGY Acquisition Corporation in its IPO?

TLGY Acquisition Corporation raised a total of $200 million in its initial public offering.

What does each unit in the TLGY IPO consist of?

Each unit consists of one Class A ordinary share and one-half of one redeemable warrant.

What sectors is TLGY focusing on for potential business combinations?

TLGY intends to focus on the global biopharma and technology-enabled business-to-consumer industries.

What is the ticker symbol for TLGY Acquisition Corporation on NASDAQ?

The ticker symbol for TLGY Acquisition Corporation is TLGYU.

Who managed the IPO for TLGY Acquisition Corporation?

Mizuho Securities acted as the sole bookrunner, and Baird was the lead manager for the offering.